PRESS RELEASE published on 05/08/2025 at 14:00, 7 months 14 days ago MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review MIRA Pharmaceuticals, Inc. announces board approval for strategic acquisition of SKNY Pharmaceuticals targeting obesity and nicotine dependence. $5 million contribution from SKNY. Merger subject to shareholder approval Acquisition Obesity MIRA Pharmaceuticals SKNY Pharmaceuticals Nicotine Dependence
BRIEF published on 05/06/2025 at 14:05, 7 months 16 days ago MIRA Pharmaceuticals Announces Absence of Neurotoxicity in Ketamir-2 Study Phase I Trial MIRA Pharmaceuticals Ketamir-2 NMDA Receptor Neurotoxicity Study
BRIEF published on 05/06/2025 at 14:05, 7 months 16 days ago MIRA Pharmaceuticals annonce l'absence de neurotoxicité dans l'étude Ketamir-2 Essai De Phase I MIRA Pharmaceuticals Ketamir-2 Récepteur NMDA Étude De Neurotoxicité
PRESS RELEASE published on 05/06/2025 at 14:00, 7 months 16 days ago MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity MIRA Pharmaceuticals announces positive preclinical results for oral NMDA receptor antagonist Ketamir-2, showing no brain toxicity. Phase I clinical trial ongoing Phase I Clinical Trial Preclinical Results MIRA Pharmaceuticals Ketamir-2 Oral NMDA Receptor Antagonist
BRIEF published on 04/23/2025 at 14:05, 7 months 29 days ago MIRA Pharmaceuticals Announces Promising Results for Ketamir-2 Topical Formulation FDA Fast Track Ketamir-2 Topical Formulation In Vitro Testing Pain Relief Market
BRIEF published on 04/23/2025 at 14:05, 7 months 29 days ago MIRA Pharmaceuticals annonce des résultats prometteurs pour la formulation topique du kétamir-2 Procédure Accélérée De La FDA Ketamir-2 Formulation Topique Tests In Vitro Marché Du Soulagement De La Douleur
PRESS RELEASE published on 04/23/2025 at 14:00, 7 months 29 days ago MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation MIRA Pharmaceuticals announces completion of IVRT for topical Ketamir-2 formulation in pain-related conditions, aiming to address market needs and regulatory considerations MIRA Pharmaceuticals Neuropathic Pain Topical Formulation IVRT FDA Guidance
BRIEF published on 04/16/2025 at 14:05, 8 months 6 days ago MIRA Pharmaceuticals Reports Promising Ketamir-2 Data for Diabetic Neuropathy Clinical Trials MIRA Pharmaceuticals Ketamir-2 Diabetic Neuropathy Non-Opioid Treatments
BRIEF published on 04/16/2025 at 14:05, 8 months 6 days ago MIRA Pharmaceuticals publie des données prometteuses sur le kétamir-2 pour la neuropathie diabétique Essais Cliniques MIRA Pharmaceuticals Ketamir-2 Neuropathie Diabétique Traitements Non Opioïdes
PRESS RELEASE published on 04/16/2025 at 14:00, 8 months 6 days ago MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion MIRA Pharmaceuticals announces strong efficacy of Ketamir-2 in diabetic neuropathy model, offering potential breakthrough treatment for patients. Phase IIa trial planned Clinical Trial MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Diabetic Neuropathy
Published on 12/22/2025 at 15:00, 5 hours 4 minutes ago World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
Published on 12/22/2025 at 14:40, 5 hours 24 minutes ago Namibia Critical Metals Inc. Receives Proceeds of $1,154,762 from Exercise of Warrants
Published on 12/22/2025 at 14:30, 5 hours 34 minutes ago Prospect Ridge Updates Diamond Drill Program at 100% Owned Camelot Copper-Gold Project in B.C.'S Cariboo Mining District
Published on 12/22/2025 at 14:00, 6 hours 4 minutes ago Rio Grande Resources Completes 2025 Field Program and Advances Drill Targeting at the Winston Gold-Silver Project
Published on 12/22/2025 at 14:00, 6 hours 4 minutes ago PPX Mining Appoints Ernest Mast as President and CEO and Announces Stock Option Grants
Published on 12/22/2025 at 19:31, 33 minutes ago EQS-Adhoc: Marley Spoon Group SE: CEO Daniel Raab Re-appointed and Contract to be Extended until June 2029
Published on 12/22/2025 at 19:00, 1 hour 4 minutes ago PATRIMOINE ET COMMERCE: Déclarations des transactions sur actions propres (hors contrat de liquidité) réalisées le 19 décembre 2025
Published on 12/22/2025 at 18:51, 1 hour 12 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 12/22/2025 at 18:20, 1 hour 44 minutes ago CGTN: How China drives high-quality development through technological innovation
Published on 12/22/2025 at 18:14, 1 hour 49 minutes ago Alzchem Group AG paves the way for continuity and further growth: Management Board contracts of Andreas Niedermaier and Andreas Lösler extended ahead of schedule
Published on 12/22/2025 at 18:33, 1 hour 31 minutes ago ABEO SE RENFORCE ET OBTIENT UNE TRÈS LARGE MAJORITÉ DU CAPITAL DE VOGO AVEC 90,84% DÉTENUS À L’ISSUE DE L’OFFRE RÉOUVERTE
Published on 12/22/2025 at 18:05, 1 hour 59 minutes ago Covivio - Treasury shares transactions between December 15th , 2025 and December 19th, 2025
Published on 12/22/2025 at 18:05, 1 hour 59 minutes ago Covivio - Déclaration des transactions sur actions propres réalisées du 15 décembre au 19 décembre 2025
Published on 12/22/2025 at 17:45, 2 hours 19 minutes ago Déclaration des transactions sur actions propres réalisées du 15 au 19 décembre 2025 dans le cadre du programme de rachat d’actions
Published on 12/22/2025 at 17:35, 2 hours 29 minutes ago DECLARATION HEBDOMADAIRE D'OPERATIONS EFFECTUEES DU 15 AU 19 DECEMBRE 2025